New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens

Virology

Volumn 395, Issue 1, 2009, Pages 97-113

  Borovkov, Alexandre ^a   Magee, D Mitch ^a   Loskutov, Andrey ^a   Cano, Jose A ^a   Selinsky, Cheryl ^a   Zsemlye, Jason ^c   Lyons, C Rick ^c   Sykes, Kathryn ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen discovery; Cowpox; DNA vaccine; Expression library immunization; Gene vaccine; Genomics; Smallpox

Indexed keywords

ANTIGEN; MEMBRANE ANTIGEN; ORTHOPOXVIRUS VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VACV 4 POX VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC IMMUNIZATION; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOGENICITY; LUNG INFECTION; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; POLYMERASE CHAIN REACTION; POXVIRUS; PRIORITY JOURNAL; PROTECTION; SMALLPOX; SPLEEN CELL; VIRUS GENOME;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; COWPOX VIRUS; FEMALE; GENE LIBRARY; GENOME, VIRAL; MICE; MICE, INBRED C57BL; OPEN READING FRAMES; T-LYMPHOCYTES; VIRAL VACCINES;

MUS; ORTHOPOXVIRUS; POXVIRIDAE; VARIOLA VIRUS;

EID: 71749116601     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.09.008     Document Type: Article

References (69)

1. Afonso C.L., Tulman E.R., Lu Z., Zsak L., Kutish G.F., and Rock D.L. The genome of fowlpox virus. J. Virol. 74 8 (2000) 3815-3831
2. Alcami A., Khanna A., Paul N.L., and Smith G.L. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80 Pt. 4 (1999) 949-959
3. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 2 (1998) 365-396
4. Barry M.A., Howell D.P.G., Anderson H.A., Chen J.L., and Singh R.A.K. Expression library immunization to discover and improve vaccine antigens. Immunol. Rev. 199 (2004) 68-83
5. Boutin Y., Leitenberg D., Tao X., and Bottomly K. Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets. J. Immunol. 159 12 (1997) 5802-5809
6. Buller R.M., and Palumbo G.J. Poxvirus pathogenesis. Microbiol. Mol. Biol. Rev. 55 1 (1991) 80-122
7. Chung C.S., Chen C.H., Ho M.Y., Huang C.Y., Liao C.L., and Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J. Virol. 80 5 (2006) 2127-2140
8. Cornberg M., Sheridan B.S., Saccoccio F.M., Brehm M.A., and Selin L.K. Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J. Virol. 81 2 (2007) 934-944
9. Dasgupta A., Hammarlund E., Slifka M.K., and Fruh K. Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class i molecules. J. Immunol. 178 3 (2007) 1654-1661
10. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., Hirst S., Villarreal L., Felgner P.L., and Crotty S. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79 18 (2005) 11724-11733
11. Demkowicz Jr. W.E., Littaua R.A., Wang J., and Ennis F.A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70 4 (1996) 2627-2631
12. Dieli F., Lio D., Sireci G., and Salerno A. Genetic control of C3 production by the S region of the mouse MHC. J. Immunogenet. 15 5-6 (1988) 339-343
13. Dunlop L.R., Oehlberg K.A., Reid J.J., Avci D., and Rosengard A.M. Variola virus immune evasion proteins. Microbes. Infect. 5 11 (2003) 1049-1056
14. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., and Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11 7 (2005) 740
15. Ferrier-Rembert A., Tournier J.N., Drillien R., Garin D., and Crance J.M. CD4+ T cells play a pivotal role in the control of cowpox virus infection in mice. Viral. Immunol. 20 1 (2007) 214-220
16. Flick-Smith H.C., Eyles J.E., Hebdon R., Waters E.L., Beedham R.J., Stagg T.J., Miller J., Alpar H.O., Baillie L.W.J., and Williamson E.D. Mucosal or parental administration of mircosphere-associated Bacillus anthracis protective antigen protects against anthrax in mice. Infect. Immun. 70 4 (2002) 2022-2028
17. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., Titball R.W., and Williamson E.D. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70 3 (2002) 1653-1656
18. Golden J.W., and Hooper J.W. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377 1 (2008) 19-29
19. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., and Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9 9 (2003) 1131-1137
20. Henderson D.A. Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis. 5 4 (1999) 537-539
21. Heraud J.-M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., Manischewitz J., King L.R., Hryniewicz A., Trindade C.J., Hassett M., Tsai W.-P., Venzon D., Nalca A., Vaccari M., Silvera P., Bray M., Graham B.S., Golding H., Hooper J.W., and Franchini G. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177 4 (2006) 2552-2564
22. Hooper J.W., Custer D.M., Schmaljohn C.S., and Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266 2 (2000) 329-339
23. Hooper J.W., Custer D.M., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 1 (2003) 181-195
24. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., Schmaljohn C.S., Schmaljohn A.L., and Jahrling P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78 9 (2004) 4433-4443
25. Jacobs A. Immunity conferred by smallpox vaccine. How long does immunity last?. BMJ 324 7346 (2002) 1157 discussion 1157 [letter; comment]
26. Janeway C., P. T., Walport M., and Schlomchik M. Immunobiology. 6th ed. 1 vols (2005), Garland Science, New York
27. Jing L., Chong T.M., McClurkan C.L., Huang J., Story B.T., and Koelle D.M. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J. Immunol. 175 11 (2005) 7550-7559
28. Joklik W.K. The purification of four strains of poxvirus. Virology 18 (1962) 9-18
29. Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B., Casey, R., Newman, F., Polack, F. P., Randolph, V. B., Deatly, A., Hackell, J., Gruber, W., Murphy, B. R., and Collins, P. L. (2005). Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191(7), 1093-104.
30. Kaufman D.R., Goudsmit J., Holterman L., Ewald B.A., Denholtz M., Devoy C., Giri A., Grandpre L.E., Heraud J.-M., Franchini G., Seaman M.S., Havenga M.J.E., and Barouch D.H. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol. 82 14 (2008) 6829-6837
31. LeDuc J.W., and Becher J. Current status of smallpox vaccine. Emerg. Infect. Dis. 5 4 (1999) 593-594
32. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79 21 (2005) 13454-13462
33. MacNeill A.L., Moldawer L.L., and Moyer R.W. The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice. Virology 384 1 (2009) 151-160
34. McFadden G. Poxvirus tropism. Nat. Rev. Micro. 3 3 (2005) 201-213
35. Moore Z.S., Seward J.F., and Lane J.M. Smallpox. Lancet 367 9508 (2006) 425-435
36. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 252 5013 (1991) 1662-1667
37. Moutaftsi M., Peters B., Pasquetto V., Tscharke D.C., Sidney J., Bui H.H., Grey H., and Sette A. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24 7 (2006) 817-819
38. Myette J.R., and Niles E.G. Domain structure of the vaccinia virus mRNA capping enzyme. J. Biol. Chem. 271 20 (1996) 11936-11944
39. Nelson G.E., Sisler J.R., Chandran D., and Moss B. Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 380 2 (2008) 394-401
40. Ojeda S., Domi A., and Moss B. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J. Virol. 80 19 (2006) 9822-9830
41. Ojeda S., Senkevich T.G., and Moss B. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80 1 (2006) 51-61
42. Oseroff C., Peters B., Pasquetto V., Moutaftsi M., Sidney J., Panchanathan V., Tscharke D.C., Maillere B., Grey H., and Sette A. Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J. Immunol. 180 11 (2008) 7193-7202
43. Parrino J., and Graham B.S. Smallpox vaccines: past, present, and future. J. Allergy Clin. Immunol. 118 6 (2006) 1320-1326
44. Pickup D.J. Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design. Expert. Rev. Vaccines 6 1 (2007) 87-95
45. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., Asher T.E., Douek D.C., Harari A., Pantaleo G., Bailer R., Graham B.S., Roederer M., and Koup R.A. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 204 6 (2007) 1405-1416
46. Pulford D.J., Gates A., Bridge S.H., Robinson J.H., and Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22 25-26 (2004) 3358-3366
47. Sakhatskyy P., Wang S., Chou T.-h.W., and Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355 2 (2006) 164-174
48. Sakhatskyy P., Wang S., Zhang C., Chou T.-H., Kishko M., and Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 371 1 (2008) 98-107
49. Shchelkunov S.N., Safronov P.F., Totmenin A.V., Petrov N.A., Ryazankina O.I., Gutorov V.V., and Kotwal G.J. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 243 2 (1998) 432-460
50. Shchelkunov S.N., Totmenin A.V., Loparev V.N., Safronov P.F., Gutorov V.V., Chizhikov V.E., Knight J.C., Parsons J.M., Massung R.F., and Esposito J.J. Alastrim Smallpox variola minor virus genome DNA sequences. Virology 266 2 (2000) 361-386
51. Slifka M.K. The future of smallpox vaccination: is MVA the key?. Med. Immunol. 4 1 (2005) 2
52. Smith G.L., and McFadden G. Smallpox: anything to declare?. Nat. Rev. 2 (2002) 521-527
53. Sykes K.F., and Johnston S.A. Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses. DNA Cell. Biol. 18 7 (1999) 521-531
54. Szajner P., Jaffe H., Weisberg A.S., and Moss B. Vaccinia virus G7L protein interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J. Virol. 77 6 (2003) 3418-3429
55. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 6365 (1992) 152-154
56. Thornburg N.J., Ray C.A., Collier M.L., Liao H.-X., Pickup D.J., and Johnston R.E. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology 362 2 (2007) 441-452
57. Tscharke D.C., Karupiah G., Zhou J., Palmore T., Irvine K.R., Haeryfar S.M.M., Williams S., Sidney J., Sette A., Bennink J.R., and Yewdell J.W. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201 1 (2005) 95-104
58. Vanderplasschen A., Mathew E., Hollinshead M., Sim R.B., and Smith G.L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. U. S. A. 95 13 (1998) 7544-7549
59. Viner K.M., and Isaacs S.N. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccines. Microbes. Infect. 7 4 (2005) 579
60. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., Schlereth B., Handley A., King L., and Hulsemann V. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 12 (2006) 2065-2070
61. Vorou R.M., Papavassiliou V.G., and Pierroutsakos I.N. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21 2 (2008) 153-156
62. Wang S., Parker C., Taaffe J., Solorzano A., Garcia-Sastre A., and Lu S. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26 29-30 (2008) 3626-3633
63. Ward J.I., Cherry J.D., Chang S.-J., Partridge S., Lee H., Treanor J., Greenberg D.P., Keitel W., Barenkamp S., Bernstein D.I., Edelman R., Edwards K., and the A. S. G. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 353 15 (2005) 1555-1563
64. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., Nichols R., Johnson C., Cruz J., Kennedy J.S., Ennis F.A., and Monath T.P. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9 9 (2003) 1125-1130
65. Wiser I., Balicer R.D., and Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 25 6 (2007) 976-984
66. Wolffe E.J., Vijaya S., and Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211 1 (1995) 53-63
67. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., Davis H.L., Braciale T.J., Eisenberg R.J., Cohen G.H., and Isaacs S.N. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25 7 (2007) 1214-1224
68. Xu R.H., Cohen M., Tang Y., Lazear E., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Sigal L.J. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205 4 (2008) 981-992
69. Zajac P., Spehner D., and Drillien R. The vaccinia virus J5L open reading frame encodes a polypeptide expressed late during infection and required for viral multiplication. Virus Res. 37 2 (1995) 163-173